Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Genes and Fibrinolytic Capacity of Human Endothelium

This study has been completed.
Information provided by (Responsible Party):
Nancy J. Brown, Vanderbilt University Identifier:
First received: August 29, 2005
Last updated: December 18, 2012
Last verified: December 2012

To conduct several studies on genes and the fibrinolytic capacity of human endothelium.

Condition Intervention
Cardiovascular Diseases
Heart Diseases
Blood Disease
Coronary Disease
Drug: angiotensin converting enzyme inhibitor

Study Type: Interventional
Study Design: Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Genes and Fibrinolytic Capacity of Human Endothelium

Resource links provided by NLM:

Further study details as provided by Vanderbilt University:

Primary Outcome Measures:
  • Net t-LA release [ Time Frame: minutes ] [ Designated as safety issue: No ]
    Net t-PA release from the forearm vasculature

Enrollment: 48
Study Start Date: August 2000
Study Completion Date: July 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Effect of smoking on t-PA release Drug: angiotensin converting enzyme inhibitor

  Show Detailed Description


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

No eligibility criteria

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00139503

Sponsors and Collaborators
Vanderbilt University
Principal Investigator: Nancy Brown Vanderbilt University
  More Information


Responsible Party: Nancy J. Brown, Professor and Chair, Department of Medicine, Vanderbilt University Identifier: NCT00139503     History of Changes
Other Study ID Numbers: 245, R01HL065193
Study First Received: August 29, 2005
Last Updated: December 18, 2012
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cardiovascular Diseases
Coronary Artery Disease
Coronary Disease
Heart Diseases
Hematologic Diseases
Arterial Occlusive Diseases
Embolism and Thrombosis
Myocardial Ischemia
Vascular Diseases
Angiotensin-Converting Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protease Inhibitors processed this record on November 24, 2014